A. Elise van Leeuwen‐Stok

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study

Lotte E. Elshof, Konstantinos Tryfonidis, Leen Slaets et al. · European Journal of Cancer · 2015 · 380 citations · Full text

Medicine, Oncology, Breast Oncology +12

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Stefanie de Groot, Rieneke T. Lugtenberg, Danielle Cohen et al. · Nature Communications · 2020 · 335 citations · Full text

Medicine, Nutritional Sciences, Oncology +17

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

Erik J. Blok, Judith R. Kroep, Elma Meershoek‐Klein Kranenbarg et al. · JNCI Journal of the National Cancer Institute · 2017 · 201 citations · Full text

Medicine, Oncology, Pharmacology +15

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group

Marije E. Hamaker, Caroline Seynaeve, A.N.M. Wymenga et al. · The Breast · 2013 · 137 citations

Medicine, Geriatric Medicine, Oncology +17

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Journal of Clinical Oncology · 2023 · 91 citations

Pharmacy, Endocrinology, Oncology +10